Institutional Biosafety Committee meets on the second Wednesday of each month from 9:00-11:00 am. Please refer to the meeting schedule for exact dates and locations. 


BUA review process may take up to 1-2 months, including EH&S site review, Biosafety Officer pre-review and Institutional Biosafety Committee review.

Federal law requires the establishment of a Institutional Biosafety Committee (IBC) at institutions where recombinant biological materials are used in research. At UCSF, the IBC is appointed by the Vice Chancellor for Research and consists of a Chair, Vice Chair, and members selected to represent the UCSF faculty, staff, and public interests, and to provide expertise in a wide variety of biological disciplines. At least two community members with no UCSF affiliation other than membership on the IBC are required, and are responsible for representing the surrounding community’s interests regarding health and environmental protection. Ex Officio members include the Director of EH&S, the Biological Safety Officer (BSO), the Director of the Animal Care Facility, and the Public Health Officer, or their designated representative. The IBC membership represents collective expertise and research experience in recombinant DNA, infectious agents, toxins, and biological safety, which are applied to the evaluation of appropriate safety measures needed for experiments that may pose potential risks to health or the environment.

The IBC is also specifically authorized by the Chancellor to limit or suspend any research that is not in compliance with UCSF biosafety policies and procedures. The IBC advises and works with EH&S in administering the various aspects of the campus Biological Safety Program.

The IBC is responsible for 1) ensuring that research conducted at UCSF is in compliance with the NIH Guidelines for Research Involving Recombinant DNA Molecules (“Guidelines”), and the Biosafety in Microbiological and Biomedical Laboratories, 5th edition (“BMBL”); 2) drafting campus biosafety policies and procedures; and 3) reviewing individual research proposals for biosafety concerns. The IBC meets monthly to review proposals from faculty at all UCSF campuses (Parnassus, Mission Bay, SFGH, Mount Zion), from affiliated Institutes (Gladstone, Gallo, Howard Hughes Medical Institute, and others) and from faculty members who work off-campus. Veterans Administration-funded projects are specifically excluded from the IBC's charge. The IBC does not oversee biosafety policies for the hospitals, clinics or clinical laboratories, but does provide consultation when requested. Biosafety policies for hospitals and clinics are the responsibility of the respective Hospital Epidemiology and Infection Control Committees.

Principal Investigators (PIs) who wish to perform research using biological materials must submit a Biological Use Authorization (BUA) application to the IBC for approval prior to beginning work. The Committee generally reviews applications that involve work at Biosafety Level 2 or 3 and the BSO and Assistant Biosafety Officers (collectively “BSOs”) review Biosafety Level 1 research applications. BSL 1 applications are usually considered exempt from committee review unless a BSO has specific concerns that warrant full Committee involvement, or if the work involves certain types of recombinant genetic work. IBC review includes an independent assessment of the containment levels required by the NIH Guidelines for the proposed research, an assessment of the laboratory facilities, procedures and practices, and a review of the training and expertise of personnel.

While the IBC cannot alter the Risk Group of an organism, it is within the IBC’s authority to raise or lower containment for the work involving the organism based upon a full risk assessment of the work being done. Recommendations for the biosafety level (BSL) of laboratory operation are often modified according to the number of infectious particles encountered in the project and the usual route of infection. As an example, purified Mycobacterium tuberculosis is classified as RG 3 because of the serious consequences of becoming infected.

Meeting Schedule- Second Wednesday of the Month, 9am-11am

2023 Schedule


January 11

February 8

March 8

April 12

May 10

June 14

July 12

August 9

September 13

October 13

November 8

December 13

All meetings are held via Zoom or Teams until
further notice.




Michael S. McGrath, MD, PhD

Chair of the IBC

Medicine/AIDS Program


Anita Sil, MD, PhD

Vice Chair of the IBC

Microbiology and Immunology


Brian E. Smith, Ex Officio

Chief Ethics and Compliance Officer

Senior Associate Vice Chancellor—Research Infrastructure and Operations, Office of Research

Zosia Zawacki, DVM

Clinical Veterinarian, LARC

Pao-Tien Chuang, PhD, MD

Cardiovascular Research Institute

Eric Collisson, M.D.


Paul Gaylord, Community Member

Senior EH&S/Risk Management Specialist

Midori Kato-Maeda, MD

Zuckerberg San Francisco General Hospital (ZSFG)

Robert Kosnik, MD, Ex Officio

Medical Director, Occupational Health Program

Sergio Baranzini, PhD


Jorge J Palop, PhD

Gladstone Institutes

John Oberschelp, Community Member

David H. Silberman, Community Member

Emeritus Director, Health & Safety Programs

Stanford University School of Medicine

Sandra Schmid, PhD

Chief Science Officer, Chan Zuckerberg Biohubivision of Experimental Medicine

Hua Su, MD

Associate Director, Center for Cerebrovascular Research

Anesthesia and Perioperative Care

Paul M. Sullam, MD

Division of Infectious Diseases, VAMC 111W

Peili Zhu, MD, PhD

UCSF Biosafety Officer, EH&S

Peter Beernink, PhD

Children’s Hospital Oakland Research Institute (CHORI)

Noriyuki Kasahara, MD, PhD

Neurological Surgery & Radiation Oncology

Charles Y. Chiu, MD, PhD

Laboratory Medicine, Box 0134

Alexander Pollen, PhD


Dora Tiet, Community Memeber

Senoir EHS/Risk Management Specialist

Barbara Woods

Committee Coordinator, EH&S





EHS Categories

Biological Safety